Inflammatory serum parameters.

<p>Serum concentrations of the inflammatory cytokines IL–6 (A) and TNF (B) as well as the and hepatic acute phase proteins fibrinogen (C) and C-reactive protein (D) in all the patients included in the study.</p

ALS disease progression.

<p>Absolute values (A) and changes from baseline (B) in ALSFRSr total score during the 12 months study period comparing the group of patients treated with ANA and the historical control.</p

Baseline characteristics of all the patients treated with ANA.

<p>Abbreviations: ALSFRSr = amyotrophic lateral sclerosis functional rating scale–revised. LMND = lower motor neuron disease. VC = respiratory viral capacity. UE = upper extremity. LE = lower extremity. n.d. = not determined.</p

Safety profile.

<p>* Intention-to-treat population; included 18 patients. The patient with abscess formation dropped out from the study. Data are n (%). PEG = percutaneous endoscopic gastrostomy.</p><p>Safety profile.</p